肿瘤细胞治疗研究
英文原题：Increased expression of CD70 in relapsed acute myeloid leukemia after hypomethylating agents.
Increased expression of CD70 in relapsed acute myeloid leukemia after hypomethylating agents.
急性髓系白血病（AML）是成人中最常见的急性白血病。
急性髓系白血病（AML）是成人中最常见的急性白血病。虽然诱导化疗可使大多数患者获得缓解，但仍有相当一部分患者会复发。因此，需要能够提高复发和难治性AML患者缓解率的新型疗法。CD70是CD27（TNF超家族成员）的天然配体，似乎是一个有前景的治疗靶点。因此，开发能够特异性靶向包括AML在内的多种肿瘤中CD70的嵌合抗原受体（CAR）T细胞治疗产品引起了相当大的兴趣。在本研究中，我们采用常规诊断技术，如免疫组织化学和流式细胞术，研究初治和接受去甲基化药物（HMA）后复发的AML患者骨髓样本中CD70的表达。此外，我们评估了HMA对CD70表达的影响，并检测了CD70在各种白血病细胞亚群和正常造血祖细胞中的表达。
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While induction chemotherapy leads to remission in most patients, a significant number will experience relapse. Therefore, there is a need for novel therapies that can improve remission rates in patients with relapsed and refractory AML. CD70 is the natural ligand for CD27 (a member of the TNF superfamily) and appears to be a promising therapeutic target. Consequently, there is considerable interest in developing chimeric antigen receptor (CAR) T-cell therapy products that can specifically target CD70 in various neoplasms, including AML. In this study, we employed routine diagnostic techniques, such as immunohistochemistry and flow cytometry, to investigate the expression of CD70 in bone marrow samples from treatment-na ve and relapsed AML patients after hypomethylating agents (HMA). Also, we evaluated the impact of HMA on CD70 expression and examined CD70 expression in various leukemic cell subsets and normal hematopoietic progenitors.
MEMBER ACCOUNT
登录成功会直接打开下一页。
